RIFINAH

This brand name is authorized in France, Hong Kong SAR China, Ireland, Malta, Netherlands, New Zealand, South Africa, Spain, UK.

Active ingredients

The drug RIFINAH contains a combination of these active pharmaceutical ingredients (APIs):

1	Rifampicin UNII VJT6J7R4TR - RIFAMPIN
	Rifampicin is an active bactericidial antituberculosis drug which is particularly active against the rapidly growing extracellular organisms and also has bactericidial activity intracellularly. Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
	Read more about Rifampicin
2	Isoniazid UNII V83O1VOZ8L - ISONIAZID
	Isoniazid is used mainly in the treatment of pulmonary tuberculosis but it appears to be effective also in the treatment of extrapulmonary lesions, including meningitis and genito-urinary disease.
	Read more about Isoniazid

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RIFINAH Coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J04AM02	Rifampicin and isoniazid	J Antiinfectives for systemic use → J04 Antimycobacterials → J04A Drugs for treatment of tuberculosis → J04AM Combinations of drugs for treatment of tuberculosis
Discover more medicines within J04AM02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	54213
FR	Base de données publique des médicaments	63898512
GB	Medicines & Healthcare Products Regulatory Agency	146592, 19240, 19242
HK	Department of Health Drug Office	27590, 27593
IE	Health Products Regulatory Authority	64386, 64394
MT	Medicines Authority	MA1359/02801, MA1359/02802
NL	Z-Index G-Standaard, PRK	93890
NZ	Medicines and Medical Devices Safety Authority	2083, 2084
ZA	Health Products Regulatory Authority	A40/20.2.3/0534, A40/20.2.3/0535